TY - JOUR
T1 - Protective effect of an enteral formula containing TGF-β2 in the prevention of chemotherapy-induced diarrhoea
T2 - A pilot study
AU - Antoun, Sami
AU - Boige, Valérie
AU - Ducreux, Michel
AU - Paintain, Morine
AU - Martin van't Hof, van't Hof
AU - Enslen, Marc
AU - Steenhout, Philippe
AU - Schiffrin, Eduardo J.
AU - Nitenberg, Gérard
N1 - Funding Information:
This study was funded by Nestec Ltd. We thank Dr Vanessa Gray-Schopfer, OmniScience SA, who provided medical writing services on behalf of Nestlé Nutrition. The authors were fully responsible for contents and editorial decisions for this manuscript.
PY - 2009/12/1
Y1 - 2009/12/1
N2 - Background and aims: Systemic chemotherapy causes enterocyte cellular damage; diarrhoea is frequent during 5-fluorouracil-based chemotherapy. A nutritional composition containing transforming growth factor beta (TGF-β2) has been proposed to alleviate clinical manifestations associated with gut barrier breakdown and malnutrition. This study aimed to show that colorectal cancer patients could benefit from a TGF-β2-enriched nutritional supplement. Methods: A randomised clinical trial was conducted, recruiting colorectal adenocarcinoma patients undergoing 5-fluorouracil-based chemotherapy. Patients received the same nutritional supplement for 3 months, except that the test formula contained 2 ng TGF-β2/mg protein. The main objective was to assess differences between the two groups in mean number of diarrhoea cycles and probability to experience diarrhoea. Results: Twenty-two patients were enrolled and randomised. Of these, 13 patients were evaluable: 4 in the control group, 9 in the test group. Three patients in the control group (75%) and 4/9 (44%) patients in the TGF-β2-containing formula group experienced at least one episode of diarrhoea. Mucositis, the number of days with diarrhoea, and the mean number of episodes in relation to product intake were lower in the TGF-β2 group. Conclusions: These preliminary data suggest that enteral TGF-β2 could efficiently reduce 5-fluorouracil chemotherapy-induced diarrhoea in colorectal cancer patients, warranting larger randomised studies.
AB - Background and aims: Systemic chemotherapy causes enterocyte cellular damage; diarrhoea is frequent during 5-fluorouracil-based chemotherapy. A nutritional composition containing transforming growth factor beta (TGF-β2) has been proposed to alleviate clinical manifestations associated with gut barrier breakdown and malnutrition. This study aimed to show that colorectal cancer patients could benefit from a TGF-β2-enriched nutritional supplement. Methods: A randomised clinical trial was conducted, recruiting colorectal adenocarcinoma patients undergoing 5-fluorouracil-based chemotherapy. Patients received the same nutritional supplement for 3 months, except that the test formula contained 2 ng TGF-β2/mg protein. The main objective was to assess differences between the two groups in mean number of diarrhoea cycles and probability to experience diarrhoea. Results: Twenty-two patients were enrolled and randomised. Of these, 13 patients were evaluable: 4 in the control group, 9 in the test group. Three patients in the control group (75%) and 4/9 (44%) patients in the TGF-β2-containing formula group experienced at least one episode of diarrhoea. Mucositis, the number of days with diarrhoea, and the mean number of episodes in relation to product intake were lower in the TGF-β2 group. Conclusions: These preliminary data suggest that enteral TGF-β2 could efficiently reduce 5-fluorouracil chemotherapy-induced diarrhoea in colorectal cancer patients, warranting larger randomised studies.
KW - 5-fluorouracil
KW - Colorectal cancer
KW - Diarrhoea
KW - TGF-β2
UR - http://www.scopus.com/inward/record.url?scp=71949129045&partnerID=8YFLogxK
U2 - 10.1016/j.eclnm.2009.10.005
DO - 10.1016/j.eclnm.2009.10.005
M3 - Article
AN - SCOPUS:71949129045
SN - 1751-4991
VL - 4
SP - e348-e350
JO - e-SPEN
JF - e-SPEN
IS - 6
ER -